AGP Executive Report
Last update: 8 hours agoCancer Care: The first European patients have received ImmunityBio’s bladder-cancer treatment Anktiva with BCG in Germany and Austria. Its conditional EU approval also covers Liechtenstein. Health Insurance: Genki has expanded its international health cover, including preventive and dental care; the policy is underwritten by Liechtenstein-based Squarelife Insurance. Antifungal Treatment: Strong European sales of Cresemba triggered a $37.5 million payment to Basilea. The medicine is approved in Liechtenstein and other European markets for serious fungal infections. Medicine Safety: The European Medicines Agency is reviewing depression and anxiety drug Deanxit after reports of movement problems and cognitive symptoms, some reportedly continuing after treatment stopped.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.